Lucence Diagnostics, A*STAR’s DxD Hub and the National Cancer Centre Singapore launched UNITED 2.0, a S$6 million program to develop a clinical whole‑genome and whole‑transcriptome sequencing tumor profiling assay with integrated AI analysis. The consortium aims to identify complex mutations and fusions across multiple tumor types and to build a minimal residual disease tool for post‑treatment monitoring. The initiative merges clinical sequencing, AI‑driven interpretation and regional clinical partnerships to accelerate precision oncology adoption in Southeast Asia. Multiomic profiling combines DNA and RNA sequencing to capture structural variants, fusions and expression signatures that single‑modality assays may miss, enhancing target identification for therapy selection.